Laurence Albiges1, Ulrich Kube2, Jean-Christophe Eymard3, Manuela Schmidinger4, Aristotelis Bamias5, Nadia Kelkouli6, Bernhard Mraz7, Styliani Florini8, Gernot Guderian9, Agnese Cattaneo10, Lothar Bergmann11. 1. Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France. Electronic address: laurence.albiges@gustaveroussy.fr. 2. Private Practice Urology, Chemnitz, Germany. 3. Institut Jean Godinot, Reims, France. 4. Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria. 5. Department of Clinical Therapeutics, Athens University, Medical School, Athens, Greece. 6. Novartis Pharma SAS, Paris, France. 7. Novartis Pharma GmbH, Vienna, Austria. 8. Novartis Hellas S.A.C.I., Athens, Greece. 9. Novartis Pharma GmbH, Nuremberg, Germany. 10. Novartis Pharma, Origgio, Italy. 11. University Hospital Frankfurt, Tumor Center Rhein-Main, Frankfurt/Main, Germany.
Abstract
AIM: To assess the efficacy and safety of everolimus in patients with metastatic renal cell carcinoma (mRCC) who failed one or two anti-VEGF therapies. PATIENTS AND METHODS: Data from four prospective, non-interventional studies conducted in Germany, France, Greece and Austria were pooled for this analysis. Patients with mRCC of any histology (clear cell or non-clear cell) were included. VEGF-refractory patients received everolimus 10mg/day until disease progression or unacceptable toxicity. The primary objective was to determine everolimus efficacy as measured by time to progression (TTP; from baseline to progression). RESULTS: The overall population comprised 632 patients; 493 patients received everolimus in the second-line setting. Most patients were of favourable/intermediate MSKCC risk (91%), had clear cell mRCC (89%), and had undergone nephrectomy (89%). Median TTP was 6.3months (95% confidence interval [CI], 5.9-6.8) for the overall population and 6.4months (95% CI, 5.8-6.9) for the second-line everolimus population. Similarly, median progression-free survival was 5.5months (95% CI, 5.0-6.1) for the overall population and 5.8months (95% CI, 5.0-6.4) for second-line everolimus population. Best tumour response (n=349) was complete or partial remission in 12% of patients and stable disease in 59% of patients. Overall population median overall survival (OS) was 11.2months (95% CI, 9.0-not reached). Commonly reported adverse events (AEs) (any grade) were stomatitis (25%), anaemia (15%) and asthenia (11%). CONCLUSIONS: Results of this pooled analysis provide evidence of safety and effectiveness of second-line everolimus in routine clinical use and support everolimus as a standard of care for VEGF-refractory patients with mRCC.
AIM: To assess the efficacy and safety of everolimus in patients with metastatic renal cell carcinoma (mRCC) who failed one or two anti-VEGF therapies. PATIENTS AND METHODS: Data from four prospective, non-interventional studies conducted in Germany, France, Greece and Austria were pooled for this analysis. Patients with mRCC of any histology (clear cell or non-clear cell) were included. VEGF-refractory patients received everolimus 10mg/day until disease progression or unacceptable toxicity. The primary objective was to determine everolimus efficacy as measured by time to progression (TTP; from baseline to progression). RESULTS: The overall population comprised 632 patients; 493 patients received everolimus in the second-line setting. Most patients were of favourable/intermediate MSKCC risk (91%), had clear cell mRCC (89%), and had undergone nephrectomy (89%). Median TTP was 6.3months (95% confidence interval [CI], 5.9-6.8) for the overall population and 6.4months (95% CI, 5.8-6.9) for the second-line everolimus population. Similarly, median progression-free survival was 5.5months (95% CI, 5.0-6.1) for the overall population and 5.8months (95% CI, 5.0-6.4) for second-line everolimus population. Best tumour response (n=349) was complete or partial remission in 12% of patients and stable disease in 59% of patients. Overall population median overall survival (OS) was 11.2months (95% CI, 9.0-not reached). Commonly reported adverse events (AEs) (any grade) were stomatitis (25%), anaemia (15%) and asthenia (11%). CONCLUSIONS: Results of this pooled analysis provide evidence of safety and effectiveness of second-line everolimus in routine clinical use and support everolimus as a standard of care for VEGF-refractory patients with mRCC.
Authors: R J Motzer; A Alyasova; D Ye; A Karpenko; H Li; B Alekseev; L Xie; G Kurteva; R Kowalyszyn; O Karyakin; Y Neron; T Cosgriff; L Collins; T Brechenmacher; C Lin; L Morgan; L Yang Journal: Ann Oncol Date: 2015-12-17 Impact factor: 32.976
Authors: Bradley A McGregor; Wanling Xie; Elio Adib; Walter M Stadler; Yousef Zakharia; Aijai Alva; M Dror Michaelson; Shilpa Gupta; Elaine T Lam; Subrina Farah; Amin H Nassar; Xiao X Wei; Kerry L Kilbridge; Lauren Harshman; Sabina Signoretti; Lynette Sholl; David J Kwiatkowski; Rana R McKay; Toni K Choueiri Journal: JCO Precis Oncol Date: 2022-02
Authors: S Nazha; S Tanguay; A Kapoor; M Jewett; C Kollmannsberger; L Wood; G Bjarnason; D Heng; D Soulières; N Reaume; N Basappa; E Lévesque; A Dragomir Journal: Curr Oncol Date: 2018-12-01 Impact factor: 3.677
Authors: Shaunna L Beedie; Chris Mahony; Heather M Walker; Cindy H Chau; William D Figg; Neil Vargesson Journal: Sci Rep Date: 2016-07-22 Impact factor: 4.379